Repligen (RGEN) Shares Outstanding (Weighted Average) (2010 - 2026)
Repligen (RGEN) reported Shares Outstanding (Weighted Average) of $56.4 million for Q1 2026, little changed year-over-year from $56.1 million in Q1 2025, and up 100113.39% quarter-over-quarter from $56234.0 in Q4 2025.
Repligen (RGEN) Shares Outstanding (Weighted Average) (2010 - 2026) Analysis & Trends
Repligen (RGEN) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $56.4 million in Q1 2026.
- Shares Outstanding (Weighted Average) for Q1 2026 came in at $56.4 million, changed 0.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $56.4 million (changed 0.41% YoY), and the FY2025 annual result was $56234.0, up 0.53% from the prior year.
- Shares Outstanding (Weighted Average) grew to $56.4 million in Q1 2026 per RGEN's latest filing, from $56234.0 in the prior quarter.
- Over five years, Shares Outstanding (Weighted Average) peaked at $56.4 million in Q1 2026 and troughed at $55353.0 in Q1 2022.
- A 5-year average of $6.7 million and a median of $55791.0 in 2024 frame the typical range for Shares Outstanding (Weighted Average).
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) gained 0.24% in 2024, then surged 100495.08% in 2025.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $55460.0 in 2022, then increased by 0.47% to $55720.0 in 2023, then climbed by 0.39% to $55937.0 in 2024, then increased by 0.53% to $56234.0 in 2025, then jumped by 100113.39% to $56.4 million in 2026.
- Business Quant data shows RGEN's Shares Outstanding (Weighted Average) at $56.4 million in Q1 2026, $56234.0 in Q4 2025, and $56265.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 354.90 Mn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | 283.14 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 819.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 145.34 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 72.00 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 174.20 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | 195.40 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 71.43 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 515.00 Mn |
| 10 | Repligen | 7.41 Bn | 6.42 Bn | 108.28 Mn | 56.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.35 Mn |
| Dec 31, 2025 | 56,234.00 |
| Sep 30, 2025 | 56,265.00 |
| Jun 30, 2025 | 56,234.00 |
| Mar 31, 2025 | 56.12 Mn |
| Dec 31, 2024 | 55,937.00 |
| Sep 30, 2024 | 56,012.00 |
| Jun 30, 2024 | 55,838.00 |
| Mar 31, 2024 | 55,791.00 |
| Dec 31, 2023 | 55,720.00 |
| Sep 30, 2023 | 55,688.00 |
| Jun 30, 2023 | 55,705.00 |
| Mar 31, 2023 | 55,590.00 |
| Dec 31, 2022 | 55,460.00 |
| Sep 30, 2022 | 55,432.00 |
| Jun 30, 2022 | 55,444.00 |
| Mar 31, 2022 | 55,353.00 |
| Dec 31, 2021 | 55,015.00 |
| Sep 30, 2021 | 55,015.00 |
| Jun 30, 2021 | 54,868.00 |